Artivion (NYSE:AORT) Reaches New 12-Month Low – Should You Sell?

Shares of Artivion, Inc. (NYSE:AORT) reached a new 52-week low on Friday. The stock traded as low as $19.04 and last traded at $19.0780, with a volume of 81,041 shares traded. The stock had previously closed at $19.40.

Analyst Ratings Changes

AORT has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, November 4th. Needham & Company LLC reissued a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group cut their price objective on Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, November 6th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Finally, Citizens Jmp reduced their target price on Artivion from $48.00 to $42.00 and set a “market outperform” rating on the stock in a report on Friday, November 6th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Artivion Price Performance

The firm has a market cap of $928.57 million, a PE ratio of -52.82 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.42 and a quick ratio of 3.02. The firm has a 50-day simple moving average of $23.02 and a 200 day simple moving average of $28.51.

Artivion (NYSE:AORT) last released its earnings results on Thursday, November 5th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million. Artivion had a negative net margin of 3.65% and a positive return on equity of 5.12%.

Insider Activity

In other Artivion news, CEO James P. Mackin sold 70,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andrew M. Green sold 11,480 shares of Artivion stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at $1,002,795.20. The trade was a 22.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 89,483 shares of company stock worth $2,529,531 in the last three months. 6.30% of the stock is currently owned by insiders.

Institutional Trading of Artivion

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. GW&K Investment Management LLC raised its stake in Artivion by 67.7% during the third quarter. GW&K Investment Management LLC now owns 1,332,672 shares of the company’s stock valued at $30,412,000 after buying an additional 538,194 shares during the last quarter. Voya Investment Management LLC purchased a new stake in shares of Artivion in the third quarter worth $207,000. Public Sector Pension Investment Board increased its holdings in shares of Artivion by 66.6% during the third quarter. Public Sector Pension Investment Board now owns 244,479 shares of the company’s stock valued at $5,310,000 after acquiring an additional 97,692 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Artivion by 39.2% during the third quarter. Royce & Associates LP now owns 889,702 shares of the company’s stock valued at $20,303,000 after acquiring an additional 250,420 shares in the last quarter. Finally, Diversified Trust Co bought a new position in shares of Artivion during the third quarter valued at $297,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.